On June 23, 2020, JCO: Oncology Practice published an article on rural cancer care as part of the State of Cancer Care in America series. "Closing the Rural Cancer Care Gap: Three Institutional Approaches," draws from the second event in the State of Cancer Care in America series and supporting literature to summarize the challenges to delivering high-quality care in rural communities, highlight institutional approaches to addressing these challenges, and update ASCO’s rural workforce data.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Association for Clinical Oncology (ASCO) recently sent a letter to House and Senate leadership urging their support for policies to increase diversity in clinical trials, including the CLINICAL TREATMENT Act (H.R. 913), in a future COVID-19 response package.
The American Society of Clinical Oncology (ASCO) today released a set of recommendations to support the oncology community as health care institutions across the United States face potentially difficult decisions around the allocation of scarce health care resources during the COVID-19 pandemic. In some geographic areas, the ongoing crisis is expected to demand more resources—including ventilators, critical and intensive care beds, and medications—than the U.S. or local health care systems can supply, and institutions will need to develop allocation decision policies as they provide care for a growing number of patients.
The Association for Clinical Oncology (ASCO) recently submitted comments in response to Part II of the Centers for Medicare & Medicaid Services’ (CMS) calendar year 2021 Advance Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies. The advance notice proposes updates and changes to the methodologies used to pay Medicare Advantage plans, Programs of All-Inclusive Care for the Elderly organizations, and Part D sponsors.
In a letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed concerns regarding two provisions in the 2021 Affordable Care Act (ACA) Notice of Benefit and Payment Parameters proposed rule. This proposal, if implemented, would update the regulatory and financial standards applied to ACA Exchanges.
The American Society of Clinical Oncology (ASCO) today released a position statement on state drug repository programs, outlining ASCO’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to help ensure that these programs are implemented appropriately, with sufficient patient protections in place.
On February 18, 106 organizations representing patients, providers, medical researchers, survivors, and families joined together to urge Congress to include the bipartisan CLINICAL TREATMENT Act (H.R. 913) in the upcoming ‘must pass’ healthcare extenders package, which is expected to pass this spring.
The American Society of Clinical Oncology (ASCO) released a statement applauding the Centers for Medicare & Medicaid Services (CMS) for reflecting recommendations in the Society’s position statement on pharmacy benefit managers (PBMs) in the agency’s 2021 and 2022 Medicare Advantage and Part D proposed rule.
On January 30, Jerome Seid, MD, FACP, testified during a hearing of the Michigan State Senate Committee on Health Policy and Human Services in support of SB 612, a bill that would make important reforms to prior authorization and step therapy protocols. Dr. Seid is a member of the Association for Clinical Oncology (ASCO) and past president of the Michigan Society of Hematology and Oncology (MSHO).
As a practicing hematologist and oncologist in Warren, Michigan, Dr. Seid provided first-hand experience to the Committee on how prior authorization impacts his patients.
The American Society of Clinical Oncology (ASCO), submitted its Patient-Centered Oncology Payment (PCOP) model for consideration by the Physician-Focused Payment Model Technical Advisory Committee (PTAC).